Recent findings: The antifungal armamentarium has markedly improved in the past 10 years and some new drugs are in the pipeline. The use of these new agents is one of the drivers of the changes in fungal epidemiology. These new antifungal drugs are discussed in this article.

Summary: A good selection of the antifungal, taking into consideration the pathogen, the host and the pharmacokinetic/pharmacodynamics of the drug, is paramount for clinical success.

Weblink here